News

These findings, while reassuring for JAK inhibitor prescription, nonetheless suggest that VTE-related recommendations for prescriptions should be maintained.

Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.

PBC patients with increased serum IgG levels at initial evaluation experienced faster disease progression and a greater probability of liver-related death.

Blood vessel inflammation directly influences incidence of age-related macular degeneration, epiretinal membrane, retinal vascular occlusion, and central serous chorioretinopathy

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

Aldeyra announces intention to resubmit NDA with new trial data in mid-year 2025.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

The treatment for wet age-related macular degeneration failed to achieve its primary endpoint in both trials.

Blieden discusses long-term patient management in glaucoma, the importance of follow-up care, and the role of advocacy in ophthalmology.

Blieden describes recent advancements in the detection and treatment of narrow-angle glaucoma at TOA 2025.

McCulley examines the latest updates on GLP-1 receptor agonists relevant for ophthalmologists and patients with ophthalmic diseases at TOA 2025.

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.

Follow-up to BALATON/COMINO indicates maintained improvement in best-corrected visual acuity and central subfield thickness 72 weeks after treatment.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study draws correlative connection between semaglutide and nonarteritic anterior ischemic optic neuropathy, more data required to show causation.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

March highlights groundbreaking advancements in ophthalmology, including FDA approvals for innovative treatments and alarming findings on pediatric eye health post-COVID.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.